Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 14:01 save search
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Published: 2020-10-13 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.66 -1.06% -1.09% 140K
|
Health Technology
|
| O: 1.01%
H: 5.5%
C: 4.96%
phase 2 positive trial topline psoriasis
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
Published: 2021-02-11 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.47%
H: 10.6%
C: -3.86%
results trial topline
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Published: 2021-02-03 (Crawled : 14:01) - globenewswire.com
VXRT | News | $0.7625 0.91% 0.9% 940K
|
Health Technology
|
| O: -53.56%
H: 17.58%
C: -9.09%
covid positive vaccine trial phase 3 phase 1 phase 2
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
PHAT | $9.02 0.56% 0.55% 470K
|
Health Technology
|
| O: 1.6%
H: 1.49%
C: 1.02%
phase 3 trial enroll
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Published: 2021-01-13 (Crawled : 14:01) - globenewswire.com
ARQT | $8.94 -1.76% -1.9% 1M
|
Health Technology
|
| O: -0.92%
H: 4.67%
C: 0.26%
dermatitis phase 3 trial treatment potential atopic dermatitis
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
Published: 2021-01-12 (Crawled : 14:01) - globenewswire.com
CLRB | $3.19 5.28% 4.72% 870K
|
Health Technology
|
| O: 4.04%
H: 1.94%
C: -1.94%
trial
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Published: 2020-12-22 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.38%
H: 0.75%
C: -3.01%
urea trial enroll
Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -10.58%
H: 2.98%
C: 2.97%
insulin phase 3 trial pharma
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
Published: 2020-12-11 (Crawled : 14:01) - globenewswire.com
SLS | $1.54 0.0% 1.5M
|
Health Technology
|
| O: -24.63%
H: 8.19%
C: -37.11%
positive trial phase 2
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT | $8.94 -1.76% -1.9% 1M
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.